There is a clean split in the palmitoylethanolamide literature that almost nobody points out. For pain, the evidence is oral. For skin, the evidence is topical.
Every meaningful human study of PEA in eczema and chronic itch used a cream. The one oral study in this space was conducted in dogs.
That distinction is the article. If you are buying PEA capsules hoping they will calm eczema, the trials being cited at you were done with something you rub on.
Key Takeaways
- A double-blind, randomised, comparator-controlled trial in 72 adults applied topical PEA (Levagen+) or a standard moisturiser twice daily for 4 weeks, and the PEA formulation significantly reduced redness, dryness and total patient-reported eczema score [1].
- A randomized, double-blind comparative trial in 60 patients with asteatotic eczema found a PEA-containing emollient improved skin capacitance and normalised a nerve perception threshold faster than a traditional emollient [2].
- The often-quoted ATOPA study of 2456 patients was observational and non-controlled by its own description [3], so its 58.6% symptom score reduction cannot be read as a treatment effect.
- An open application observation in 22 patients with chronic itch reported an average 86.4% itch reduction with a PEA cream [4]. Open-label, no control group.
- The only oral evidence is veterinary: an open-label study of 160 dogs with atopic dermatitis given ultra-micronized PEA orally for 8 weeks [5].
The Best Topical Trial
Eczema is clinically characterised by itchy, dry, rough and scaling skin arising from a range of underlying phenotypes [1]. The strongest study of PEA here was a double-blind, randomised, comparator-controlled trial evaluating a topical PEA formulation against a standard moisturiser [1].
Seventy-two participants over 18 with atopic eczema on their hands or arms, with symptoms including redness, dry skin, scaling or itchiness, were randomly allocated to the PEA formulation or the comparator cream [1]. Treatment was applied to the affected area twice daily for 4 weeks, with outcomes measured by a self-assessed eczema area severity index and the Patient-Oriented Eczema Measure [1]. The trial is registered as NCT05003453 [1].
The PEA formulation significantly reduced redness, dryness and total patient-reported score compared with the comparator cream [1].
Note what the comparator was. Not a placebo vehicle, but a standard moisturiser, which is an active treatment for eczema in its own right. Beating a moisturiser is a harder test than beating nothing, and that makes the result more interesting rather than less.
The trial was funded and the product supplied by Gencor Pacific, the maker of Levagen+, so independent replication would add confidence [1].
The Asteatotic Eczema Trial
Asteatotic eczema is the dry, cracked, itchy skin pattern common in older adults, usually treated with emollients containing urea, lactic acid or a lactate salt [2]. A monocentric, randomized, double-blind comparative trial in 60 patients compared a PEA and N-acetylethanolamine emollient against a traditional emollient over 28 days, using clinical scoring and bioengineering measurement [2].
Research note: In a trial of a topical PEA product for itchy dry skin, pruritus scores improved significantly after two weeks, but 13 people in the treated and control groups reported worsening of itch, stinging, scaling or redness [6].
Both groups improved on some measures, and the PEA group showed better change in skin surface capacitance, a hydration measure [2]. The finding the authors flag as most impressive was different: the PEA emollient raised the 5 Hz current perception threshold back to a normal level after 7 days, with a significant difference from baseline by 14 days [2]. That threshold correlated positively with skin surface hydration and negatively with transepidermal water loss in the PEA group [2].
Current perception threshold is a measure of sensory nerve function, and normalising it is a more specific claim than “the skin felt better”. It is consistent with the mechanistic story told about PEA in skin, where cannabinoid receptors on cutaneous sensory nerve fibres are the proposed target [4].
The Big Study That Proves Less Than It Looks
The most quoted number in this area comes from the ATOPA study, which gathered data from 2456 patients with mild to moderate atopic eczema aged 2 to 70 [3]. Intensities of redness, itch, excoriation, scaling, lichenification and dryness were significantly reduced, with a combined score reduction of 58.6% [3]. Patient-reported itch fell from 4.9 to 2.7 within 6 days and to 2.0 by study end [3]. Sleep quality improved significantly [3]. Topical corticosteroids were omitted entirely by 56% of patients, and average weekly application rate fell by 62% [3]. Tolerance was rated very good or good in 92% of cases [3].
Those are impressive figures and they come with a design that cannot support causal claims. The study describes itself as a multinational, multicentre, observational, non-controlled, prospective cohort study [3]. Every participant got the cream. Nobody was randomized to anything else.
Eczema fluctuates. People enrol when it is bad. Being handed a free product and asked to apply it regularly changes behaviour on its own. All of that produces improvement in an uncontrolled cohort regardless of the active ingredient. The steroid-reduction figure is the most interesting number in the study and equally cannot be attributed to the cream without a control arm.
The Itch Observation
Chronic, therapy-resistant itch often fails to respond to standard measures, and the discovery of cannabinoid receptors on cutaneous sensory nerve fibres made cannabinoid agonists a rational option to try [4]. In an open application observation, 22 patients with prurigo, lichen simplex and pruritus applied an emollient cream containing PEA [4]. A good antipruritic effect was documented in 14 of the 22, with an average itch reduction of 86.4% [4]. Therapy was well tolerated, with no burning or contact dermatitis observed [4].
Across reviewed topical PEA studies, mild local reactions such as stinging, redness or burning were reported in nine people [6].
An 86.4% average reduction is the sort of figure that ends up on product pages stripped of context. The context is that this was an open application observation in 22 people with no control group and no blinding, and that the effect was documented in 14 of them rather than all 22 [4]. With no control group, a placebo response cannot be ruled out [3].
The Only Oral Evidence Is in Dogs
The one study of oral PEA for atopic skin disease was conducted in animals. Clinicians from 39 veterinary clinics enrolled 160 dogs with non-seasonal atopic dermatitis and moderate itch into an 8-week open-label multicentre study of oral ultra-micronized PEA [5].
Mean itch score fell from 5.7 to 3.63 (P less than 0.0001), with 58% of dogs showing more than a 2 cm reduction and 30% reaching absent-to-very-mild itch by day 56 [5]. Mean lesion index decreased significantly, reaching the remission range in 62% of dogs, and quality of life scores improved with 45% of dogs reaching values described for healthy animals [5]. Tolerability was good to excellent, with 4 dogs experiencing reversible treatment-associated adverse events [5].
This is a genuinely interesting dataset and it has two hard limits. It is open-label with no control group, so owner and clinician expectation are uncontrolled. And the subjects are dogs. Canine atopic dermatitis is a real model for the human disease, but a veterinary open-label study is not evidence that an oral capsule improves human eczema. This site covers PEA for pets separately, where this study is the primary source.
Putting the Split to Work
If your interest is skin, the evidence points to topical formulations, where two randomized controlled trials found benefit against active comparators [1][2]. Those are the studies to weigh, and they tested creams applied twice daily for 4 weeks and 28 days respectively.
If your interest is oral PEA for skin, the honest answer is that the human trials do not exist yet. What exists is an uncontrolled human cohort using a cream [3], an open observation using a cream [4], and an open-label study in dogs using capsules [5]. That is a gap in the literature, not a hidden benefit.
Eczema that is worsening, infected or unresponsive needs dermatological care rather than a supplement decision, and the steroid-reduction figures in the observational cohort should not be read as licence to stop prescribed treatment [3].
Frequently Asked Questions
Does PEA cream help eczema?
A double-blind randomized trial in 72 adults found a topical PEA formulation significantly reduced redness, dryness and total patient-reported score compared with a standard moisturiser over 4 weeks [1].
Will PEA capsules help my eczema?
No human trial has tested that. The oral evidence in atopic skin disease comes from an open-label study in 160 dogs [5].
What about the study with 2456 patients?
The ATOPA study was observational and non-controlled by its own description, so its 58.6% symptom reduction and 56% steroid-omission figures cannot be attributed to the cream [3].
Is there evidence for itch specifically?
An open application observation in 22 patients with chronic itch reported a good effect in 14, averaging 86.4% reduction, with no control group and no blinding [4]. The asteatotic eczema trial adds a controlled measure of sensory nerve threshold normalising within 7 days [2].
How long were the topical trials?
Four weeks in the comparator-controlled eczema trial [1] and 28 days in the asteatotic eczema trial [2].
References
- Rao A, Moussa AA, Erickson M, Briskey D. Efficacy of Topical Palmitoylethanolamide (Levagen+) for the Management of Eczema Symptoms: A Double-Blind, Comparator-Controlled, Randomized Clinical Trial. Skin Pharmacol Physiol (2023). PMID 38408443
- Yuan C, Wang XM, Guichard A, et al. N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients. Clin Interv Aging (2014). PMID 25071367
- Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol (2008). PMID 18181976
- Ständer S, Reinhardt HW, Luger TA. Topical cannabinoid agonists: an effective new possibility for treating chronic pruritus. Hautarzt (2006). PMID 16874533
- Noli C, Della Valle MF, Miolo A, et al. Efficacy of ultra-micronized palmitoylethanolamide in canine atopic dermatitis: an open-label multi-centre study. Vet Dermatol (2015). PMID 26283633
- Sivesind TE et al. Cannabinoids for the Treatment of Dermatologic Conditions. JID innovations : skin science from molecules to population health (2022). PMID 35199092
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.